Core Points - Mainz Biomed N.V. has successfully closed a follow-on offering of 1,367,521 units, generating approximately $8.0 million in gross proceeds [1] - Each unit was sold at an effective price of $5.85, which includes one ordinary share and two types of warrants [1] - The Class A and Class B warrants are both immediately exercisable at the same price and have different expiration conditions [1] Company Overview - Mainz Biomed specializes in molecular genetics diagnostics, focusing on early cancer detection [3] - The flagship product, ColoAlert®, is a non-invasive test for colorectal cancer, currently marketed in Europe [3] - The company is conducting a pivotal FDA clinical study for regulatory approval in the U.S. and is developing PancAlert, a pancreatic cancer screening test [3]

Mainz Biomed N.V. MYNZ announced a 1-for-40 reverse stock split, effective Dec. 3. The company specializes in the early detection of cancer.Last month, Mainz Biomed reported a collaborative agreement with Thermo Fisher Scientific Inc. TMO through its subsidiary Life Technologies Corporation.The collaboration agreement will enable Mainz Biomed and Thermo Fisher to jointly develop and potentially commercialize Mainz Biomed’s Next Generation colorectal cancer screening product.The collaboration will harness Th ...

BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced a 1-for-40 reverse stock split of its issued and outstanding shares. The reverse stock split was authorized by the Board of Directors of the Company pursuant to shareholder approval granted at its Extraordinary Shareholders Meeting on November 20, 2024. The reverse stock ...

Revenue increases 4% year over year while loss from operations decreases by 32% Pooled Results of ColoFuture and eAArly DETECT studies published at ASCO showing groundbreaking performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Company highlights its path to success for 2025 BERKELEY, Calif. and MAINZ, Germany, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diag ...

Exhibit 99.2 Mainz Biomed N.V. Consolidated Statements of Financial Position (Unaudited) (Expressed in US Dollars) | | | | | December | | --- | --- | --- | --- | --- | | | | June 30, | | 31, | | | Note | 2024 | | 2023 | | ASSETS | | | | | | Current Assets | | | | | | Cash | | $ 977,764 | | $ 7,070,925 | | Trade and other receivables, net | 4 | 139,414 | | 93,555 | | Inventories | 5 | 520,531 | | 613,638 | | Prepaid expenses and other current assets | 6 | 751,994 | | 1,201,778 | | Total Current Assets | | 2, ...

BERKELEY, Calif. and MAINZ, Germany, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, today released a statement to shareholders highlighting its strategic plans for maximizing shareholder value, clinical developments, and its upcoming FDA trial anticipated for 2025, which aims to pave the way for entry into the U.S. market. Management believes 2025 will be a transformat ...

BERKELEY, Calif. and MAINZ, Germany, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the addition of Petra Smeltzer Starke as a Brand Ambassador for the Company. As Brand Ambassador she will help the Company in the development and dissemination of messaging focused on the importance of early detection of colorectal cancer. "We are excited about Petra jo ...

BERKELEY, Calif. and MAINZ, Germany, July 25, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in early detection of cancer, today announced significant improvements to its ColoAlert product, currently being commercialized across Europe and in select international markets. These updates aim to enhance customer satisfaction and streamline lab operations. To increase screening/lab efficiency, Mainz Biomed has introduced a novel DNA stabilizing buf ...

MC Services AG Anne Hennecke/Caroline Bergmann +49 211 529252 20 mainzbiomed@mc-services.eu For investor inquiries, please contact info@mainzbiomed.com Forward-Looking Statements Certain statements made in this press release are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "pr ...

On the basis of its positive clinical studies Mainz Biomed has now defined the final configuration including its novel mRNA biomarkers of the Next Generation Test to be used in pivotal registration study ReconAAsense A recent clinical analysis of this new configuration demonstrates sensitivity for colorectal cancer of 97% and 88% for advanced adenomas, with specificity of 93% BERKELEY, Calif. and MAINZ, Germany, July 09, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnos ...